Aducanumab - Biogen

Drug Profile

Aducanumab - Biogen

Alternative Names: Anti-beta amyloid monoclonal antibody - Biogen Idec; BART; BIIB 037; NI-10

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(Early-stage disease) in Australia (IV, Infusion)
  • 02 Nov 2017 New efficacy data from the long-term extension phase Ib PRIME trial in Alzheimer’s disease released by Biogen
  • 23 Oct 2017 Eisai exercises its option to co-develop and co-promote aducanumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top